Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis

SIMPLE SUMMARY: This review will summarise the landmark clinical trials leading to the first tissue-agnostic approval of immune checkpoint inhibitors in specific molecular profiles of recurrent endometrial cancer (EC). As this treatment is a novel therapy and yet to be integrated into routine clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Racheal Louise, Ganesan, Subhasheenee, Thangavelu, Amudha, Theophilou, Georgios, de Jong, Diederick, Hutson, Richard, Nugent, David, Broadhead, Timothy, Laios, Alexandros, Cummings, Michele, Orsi, Nicolas Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527181/
https://www.ncbi.nlm.nih.gov/pubmed/37760602
http://dx.doi.org/10.3390/cancers15184632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527181/
https://www.ncbi.nlm.nih.gov/pubmed/37760602
http://dx.doi.org/10.3390/cancers15184632

Ejemplares similares